陈超;招建华;卓文燕;张洁;

• 1:珠海市人民医院(暨南大学附属珠海医院)

摘要(Abstract)：

目的探讨轻、中、重度阿尔茨海默病(AD)患者的脑⁽¹⁸⁾F-FDG正电子发射断层显像(PET/CT)特点。方法对10例AD患者和10例健康对照的脑(18)F-FDG正电子发射断层显像(PET/CT)特点。方法对10例AD患者和10例健康对照的脑⁽¹⁸⁾F标记的脱氧葡萄糖正电子发射断层显像((18)F标记的脱氧葡萄糖正电子发射断层显像(⁽¹⁸⁾F-FDG PET)进行视觉分析,测量感兴趣区的FDG标准化摄取值(SUV),并通过计算获得其与同侧小脑FDG的SUV的比值,比较组间是否有显著性差异。结果轻度AD患者的FDG摄取代谢降低区为后扣带回及楔前叶,且呈双侧不对称性,中度AD患者的颞叶、顶叶FDG代谢降低双侧对称且降低明显,重度AD患者全脑皮质代谢明显降低。结论 AD患者的(18)F-FDG PET)进行视觉分析,测量感兴趣区的FDG标准化摄取值(SUV),并通过计算获得其与同侧小脑FDG的SUV的比值,比较组间是否有显著性差异。结果轻度AD患者的FDG摄取代谢降低区为后扣带回及楔前叶,且呈双侧不对称性,中度AD患者的颞叶、顶叶FDG代谢降低双侧对称且降低明显,重度AD患者全脑皮质代谢明显降低。结论 AD患者的⁽¹⁸⁾F-FDG PET脑显像特征反映认知功能的损害程度,是临床诊断和评估AD的有力工具。

关键词(KeyWords)： 阿尔茨海默病;正电子发射断层显像;脑;葡萄糖代谢;病程发展

Abstract:

Keywords:

基金项目(Foundation): 珠海市医学科研基金项目(编号:2016J029)

作者(Authors): 陈超;招建华;卓文燕;张洁;

参考文献(References)：

• [1] MOHSEN NAGHAVI.Global,regional,and national burden of Alzheimer’s disease and other dementias,1990-2016:a systematic analysis for the Global Burden of Disease Study 2016[J].Lancet Neurology,2019,18:88-106.DOI:10.1136/bmj.l94.
• [2] CHENG H D,WANG K.Approach to early diagnosis in amnestic mild cognitive impairment:from molecular,imaging to behavioral neurology[J].Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi,2010,10:155-159.DOI:10.3969/j.issn.1672-6731.2010.10.004.
• [3] TOLEDO J B,SHAW L M,Trojanowski JQ.Plasma amyloid beta measurements-a desired but elusive Alzheimer' s disease bio-marker[J].Alzheimers Res Ther,2013,5,8.DOI:10.1186/alzrt162.
• [4] REMBACH A,WATT AD,WILSON WJ,et al.Plasma amyloid-beta levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden[J].J Alzheimers Dis,2014,40:95-104.DOI:10.3233/JAD-131802.
• [5] FIORINL M,BONGIANNI M,BENEDETTI M D,et al.Reappraisal of Aβ40 andAβ42 peptides measurementsfluid of patient with Alzhermer’sdisease[J].JAlzheimerDisease,2018,66(1):219-227.DOI:10.3233/JAD-180616.
• [6] LI W,XIAO S F.The developments and changes in the diagnostic criteria for Alzheimer disease[J].Chin J Diagn,2015,3(2):114-117.DOI:10.1001/archneur.63.1.15
• [7] WIMO A,WINBLAD B,AGUERO-TORRES H,et al.The magnitude of dementia occurrence in the world[J].Alzheimer Dis Assoc Disord,2003,17(2):63-67.DOI:10.1097/00002093-200304000-00002
• [8] JACK CR J R,KNOPMAN D S,JAGUST W J,et al.Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade[J].Lancet Neurol,2010,9:119-128.DOI:10.1016/S1474-4422(09)70299-6.
• [9] MOSCONI L,DE SANTI S,LI J,et al.Hippocampal hypometabolism predicts cognitive decline from normal aging[J].Neurobiol Aging,2006,29:676-692.DOI:10.1016/j.neurobiolaging.2006.12.008.
• [10] 杨承源,杨惠林,许丽珍,等.即刻早期基因Arc/A rg3.1的表达及与阿尔茨海默病关系的研究进展[J].中国实用神经疾病杂志,2018,21(3):331-335.
• [11] DRZEZGA A,GRIMMER T,RIEMENSCHNEIDER M,et al.Prediction of individual clinical outcome in MCI by means ofenetic assessment and18F-FDG PET[J].J Nucl Med,2005,46:1625-1632.DOI:10.1037/0022-0006x.51.3.331.
• [12] BRAAK H,ALAFUZOFF I,ARZBERGER T,et al.Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections andimmunocytochemistry[J].Acta Neuropathol,2006,11(4):389-404.DOI:10.3410/f.1040098.489015.
• [13] MARQUIE M,SIAO TICK CHONG M,ANTON-FERNANDEZ A,et al.[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging[J].Acta Neuropathol,2017,134(4):619-628.DOI:10.1007/s00401-017-1740-8.
• [14] NELSON P T,ALAFUZOFF I,BIGIO EH,et al.Correlation of Alzheimer dis neuropathologic changes with cognitive status:a review of the literature[J].J Neuropathol Exp Neurol,2012,71(5):362-381.DOI:10.1097/NEN.0b013e31825018f7.
• [15] CHO H,CHOI J Y,HWANG MS,et al.In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum[J].Ann Neurol,2016,80(2):247-258.DOI:10.1002/ana.24711.
• [16] OSSENKOPPELE R,SCHONHAUT D R,SCHOLL M,et al.Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease[J].Brain,2016,139(Pt 5):1551-1567.
• [17] HALL B,MAK E,CERVENKA S,et al.In tau PET imaging in dementia:pathophysiology,radiotracer quantification,and a systematic review of clinical findings[J].Ageing Res Rev,2017.36:50-63.DOI:10.1016/j.arr.2017.03.002.
• [18] KLUNK W E,ENGLER H,NORDBERG A,et al.Imaging brain amyloid in Alzheimer' s disease with Pittsburgh Compound-B[J].Ann Neurol,2004,55:306-319.DOI:10.1002/ana.20009.
• [19] FAGAN A M,MINTUN M A,SHAH A R,et al.Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cogni-tively normal individuals:implications for future clinical trials of Alzheimer's disease[J].EMBO Mol Med,2009,1:371-380.DOI:10.1002/emmm.200900048.
• [20] FORSBERG A,ENGLER H,ALMKVIST O,et al.PET imaging of amyloid deposition in patients with mild cognitive impairment[J].Neurobiol Aging,2008,29:1456-1465.DOI:10.1016/j.neurobiolaging.2007.03.029.
• [21] DUKART J,MUELLER K,VIILLRINGER A,et al.Alzheimer's Disease Neuroimaging Initiative.Relationship between imaging biomarkers,age,progression andsymptom severity in Alzheimer's disease[J].Neuroimage Clin,2013,3:84-94.DOI:10.1016/j.nicl.2013.07.005.
• [22] CHETELAT G,EUSTACHE F,VIADER F,et al.FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment[J].Neurocase,2005,11:14-25.DOI:10.1080/13554790490896938.
• [23] PLASSMAN B L,LANGA K M,MCCAMMOM R J,et al.Incidence of dementia and cognitive impirment,not dementia in the United States[J].Neurology,2011,77(21):1906-1912.DOI:10.1016/j.jalz.2011.06.2625.
• [24] CHEFFBN X,ZHOU Y,WANG R,et al.Potential clinical value of maultiparametric pet in the a prediction of Alzheimer’s disease progression[J].PloS One,2016,11(5):e0154406.DOI:10.1371/journal.pone.0154406.
• [25] BLOUDEK LM,SPACKMAN D E,BLANKENBURG M,et al.Review and metaanalysis of biomarkers and diagnosticimaging in Alzheimer's disease[J].J Alzheimers Dis,2011,26:627-645.DOI:10.3233/JAD-680110.
• [26] CAROLI A,PRESTIAA A,CHEN K,et al.Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18FFDG PET:head-to-head comparison[J].J Nucl Med,2012,53(4):592.DOI:10.2967/jnumed.111.094946.
• [27] MOSCONI L,TSUI WH,HERHOLZ K,et al.Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment,Alzheimer's disease,and other dementias[J].J Nucl Med,2008,49:390-398.DOI:10.2967/jnumed.107.045385.
• [28] 井初雅,井长信,方杰,等.神经免疫在阿尔茨海默病中的作用研究进展[J].中国实用神经疾病杂志,2019,22(3):330-336.